Bio-Path Holdings, Inc. announced that on October 28, 2014, Gillian Ivers-Read, BSc. resigned from her position as a member of the Board and all committees of the Board on which she served. Ms. Ivers-Read's resignation was not because of a disagreement with the Company on any matters relating to the Company's operations, policies, or practices. On November 3, 2014, the Board, upon the recommendation of the Company's nominating/corporate governance committee appointed Dr. Sing to the Board to fill the newly created vacancy caused by the Director Resignation. Dr. Sing was also appointed as a member of the Audit Committee, the
Nominating Committee and the Company's compensation committee. Dr. Sing currently serves as Senior Director of Medical Affairs at Genomic Health, Inc.
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the bodyâs enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Companyâs second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
BIO-PATH HOLDINGS, INC. 
